No Data
No Data
Bears Are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations
Exagen Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Increased Its FY24 Revenue Outlook Above Estimates.
Express News | Exagen Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Increased Its FY24 Revenue Outlook Above Estimates
There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 38% Share Price Rise
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $7
No Data